MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
DocStyle Announces DocStyle AI: Document Productivity Tools, Accessible from the AI Assistants Lawyers Already Use19.8.2026 16:00:00 CEST | Press release
The new solution connects DocStyle's document engine to Claude for Word, Microsoft Copilot, and a dedicated chat pane, available for pre-order today ahead of general availability on October 1st. MIAMI, FL / ACCESS Newswire / August 19, 2026 / DocStyle, a leading provider of legal document repair, structuring, and automation solutions, today announced DocStyle AI. Rather than embedding a general AI chat into its software, DocStyle made its full document productivity engine accessible from the AI assistants legal professionals already use, including Claude for Word and Microsoft Copilot, alongside a dedicated DocStyle AI chat pane inside the DocStyle Ribbon. Built on the Model Context Protocol (MCP), an open standard, DocStyle AI is vendor-independent by design, staying reachable as AI models change and protecting the customer's investment. "We have always known that when making substantive changes to Word documents, you have to be inside Microsoft Word," said Chris Cangero, CEO of DocSt
Europe SPAC Summit 2026 to Convene Leading SPAC Sponsors, Investors, and European Growth Companies in Zurich on December 1019.8.2026 15:00:00 CEST | Press release
One-Day, Invitation-Only Summit Maps the Path from European Innovation to U.S. Capital Markets NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / August 19, 2026 / As a landmark year for European companies in the U.S. public markets continues to build momentum, the Europe SPAC Summit will convene the dealmakers driving the region's de-SPAC renaissance, turning its focus to deal flow, capital formation, and every stage of the path from European innovation to a thriving U.S. listing. The invitation-only Summit takes place on Thursday, December 10, 2026, at The Dolder Grand in Zurich, Switzerland, co-hosted by AUM Advisors and MBP Global. The Summit features a keynote session with Kyivstar, Ukraine's largest mobile operator, whose successful Nasdaq listing through a merger with a SPAC sponsored by Cohen Circle, the investment platform founded by fintech pioneer Betsy Cohen, demonstrates that this approach can create real value for Europe's growth companies. The program also includes
SMBs Attract Talent with AI Upskilling as Large Firms Cut Jobs and Benefits, Study Finds18.8.2026 12:00:00 CEST | Press release
General Assembly study finds role-specific AI training is the most effective approach for SMBs NEW YORK CITY, NY / ACCESS Newswire / August 18, 2026 / Small-to-medium employers (SMBs) see their human talent as a key area of investment for the AI era and are seeing strong impact from role-specific AI training, according to new research from General Assembly, a global leader in practical AI skills training. Layoff and benefit reductions at larger companies have made it easier for SMBs to recruit and retain top talent, say 81% of human resources (HR) leaders at SMBs, while nearly half (47%) of SMBs have already hired from larger firms in the past year. "Growth-stage companies see AI adoption as a catalyst, not a cost-cutting exercise," said Daniele Grassi, CEO of General Assembly. "They're able to move faster to implement AI and scale it quickly, and they're upskilling their workforces accordingly. As talent sees daily headlines around layoffs and benefit reductions, they're increasingly
LiberNovo Previews Support Week 2026, Putting Better Ergonomic Support Within Reach18.8.2026 10:00:00 CEST | Press release
Support Week starts August 25. We've got your back. HONG KONG, HK / ACCESS Newswire / August 18, 2026 / One size does not fit all. Yet most ergonomic chairs are still built around a standard frame, leaving taller, broader, and heavier users adapting to the chair instead of the chair adapting to them. LiberNovo is addressing that gap with the Maxis Series, the lead range for LiberNovo Support Week 2026, opening August 25 across the European Union and United Kingdom. Built for Bigger Builds Maxis was engineered at full scale, not adapted from a standard chair platform. A 52 cm seat depth provides greater thigh support, while a wider seat cushion gives users more room to shift naturally. Its reinforced frame supports up to 181 kg. Maxis also features a five-stage recline control system from 105° to 160°, supported by a Segmented Support System using progressive springs. This provides controlled, consistent support throughout the recline range, even under heavier loads. Three configuration
IFS Softeon Announces Successful First Go-Live with BF Global Group in Europe13.8.2026 14:00:00 CEST | Press release
First deployment marks a major milestone in strategic multi-site warehouse modernisation initiative. RESTON, VA / ACCESS Newswire / August 13, 2026 / IFS Softeon, the warehouse management system (WMS) provider delivering visibility from the boardroom to the warehouse floor, today announced the successful go-live of its warehouse management system at the first BF Global Group distribution centre, marking a significant milestone in the companies' strategic partnership announced earlier this year. The first deployment supports a leading premium stroller and baby products brand and represents the initial phase of BF Global Group's broader rollout of IFS Softeon Warehouse Management System across facilities throughout Europe in partnership with Lanark. The implementation was completed through a carefully coordinated weekend cutover, with operations transitioning successfully to the new platform. Since go-live, the facility has successfully processed and shipped both B2B and B2C customer ord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom